Citations

Clear

6273 citation(s) found for "To, Andrew".

Biventricular catheterization combined with pressure‐volume loop monitoring provides insight into the dynamic effects of left ventricular assist devices ramp on right ventricular function
Garmany, Armin , Inglis, Sara S. , Rosenbaum, Andrew , Rosenbaum, Andrew N , Inglis, Sara S , Behfar, Atta

Mayo Clinic

Catheterization and Cardiovascular Interventions | March 10, 2024 | Volume: 103 | Issue: 5 | Pages: 799-802

10.1002/ccd.30993 | PMID 38461378 Get It

AbstractRamp studies are utilized for speed optimization of continuous flow left ventricular assist devices (CF‐LVADs). We here report the utility of combined left and right heart catheterization during a ramp study to ensure a comprehensive understanding of the hemodynamic implications on both ventricles. Pressure‐volume loop (PV loop) monitoring uncovered compromised systolic and mildly compromised right ventricular function with increasing LVAD speeds, despite improvement in left ventricular unloading. These findings informed patient management and highlight the potential utility of PV loop monitoring as an adjunct to left and right heart catheterization during ramp studies of next‐generation LVADs.
Professional Employment With Left Ventricular Assist Device Support: Does Working With an LVAD Allow It to Work Too?
Inglis, Sara S. , Rosenbaum, Andrew , Rosenbaum, Andrew N , Inglis, Sara S

Mayo Clinic

ASAIO Journal | March 8, 2024 | Volume: 70 | Issue: 5 | Pages: 356-357

10.1097/mat.0000000000002187 | PMID 38457524 Get It

Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia
Ahmed, Reham, Feldman, Andrew L. , Feldman, Andrew L

Mayo Clinic

Blood | March 7, 2024 | Volume: 143 | Issue: 10 | Pages: 938-938

10.1182/blood.2023022971 | PMID 38451510 Get It

Individualized prediction of critical illness in older adults: Validation of an elders risk assessment model
Boswell, Christopher L. , Hanson, Andrew C. , Barwise, Amelia , Herasevich, Svetlana , Minteer, Sarah A. , Barwise, Amelia K , Dong, Yue , Gajic, Ognjen

Mayo Clinic

Journal of the American Geriatrics Society | March 7, 2024 | Volume: 72 | Issue: 6 | Pages: 1839-1846

10.1111/jgs.18861 | PMID 38450712 Get It

Abstract Background The electronic health record (EHR) presents new opportunities for the timely identification of patients at high risk of critical illness and the implementation of preventive strategies. This study aims to externally validate an EHR‐based Elders Risk Assessment (ERA) score to identify older patients at high risk of future critical illness during a primary care visit. Methods This historical cohort study included patients aged ≥65 years who had primary care visits at Mayo Clinic Rochester, MN, between July 2019 and December 2021. The ERA score at the time of the primary care visit was used to predict critical illness, defined as death or ICU admission within 1 year of the visit. Results A total of 12,885 patients were included in the analysis. The median age at the time of the primary care visit was 75 years, with 44.6% being male. 93.7% of participants were White, and 64.2% were married. The median (25th, 75th percentile) ERA score was 4 (0, 9). 11.3% of study participants were admitted to the ICU or died within 1 year of the visit. The ERA score predicted critical illness within 1 year of a primary care visit with an area under the receiver operating characteristic curve of 0.84 (95% CI 0.83–0.85), which indicates good discrimination. An ERA score of 9 was identified as optimal for implementing and testing potential preventive strategies, with the odds ratio of having the primary outcome in patients with ERA score ≥9 being 11.33 (95%CI 9.98–12.87). Conclusions This simple EHR‐based risk assessment model can predict critical illness within 1 year of primary care visits in older patients. The findings of this study can serve as a basis for testing and implementation of preventive strategies to promote the well‐being of older adults at risk of critical illness and its consequences.
Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components
Wheeler, Allison P. , Snyder, Edward L. , Refaai, Majed A. , Cohn, Claudia S. , Poisson, Jessica , Fontaine, Magali J. , Sehl, Mary E. , Uhl, Lynne , Fenelus, Maly , Coyle, Thomas, Becker, Joanne , Jeng, Michael , Young, Pampee P. , OʼBrien, Jennifer , Schiller, Gary J. , Roback, John D. , Malynn, Elizabeth, Jackups, Ronald , Avecilla, Scott T. , Bentow, Stanley, Varrone, Jeanne, Fontaine, Magali , Fenelus, Maly , Jeng, Michael , Spencer, Bryan R , O'Brien, Jennifer J, Roback, John D , Avecilla, Scott T , Benjamin, Richard J , Cohn, Claudia S , Wheeler, Allison P , Nooka, Ajay K. , Spinella, Philip C. , Liles, Darla , Gehrie, Eric A , Spencer, Bryan R. , Johnson, Andrew, Liu, Kathy , Corash, Laurence M

Mayo Clinic

Blood Advances | March 6, 2024 | Volume: 8 | Issue: 9 | Pages: 2290-2299

10.1182/bloodadvances.2023012425 | PMID 38447116 Get It

Abstract Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen–reduced platelet components (PRPCs) do not potentiate pulmonary dysfunction compared with conventional platelet components (CPCs). A prospective, multicenter, open-label, sequential cohort study evaluated the incidence of treatment-emergent assisted mechanical ventilation initiated for pulmonary dysfunction (TEAMV-PD). The first cohort received CPC. After the CPC cohort, each site enrolled a second cohort transfused with PRPC. Other outcomes included clinically significant pulmonary adverse events (CSPAE) and the incidence of treatment-emergent acute respiratory distress syndrome (TEARDS) diagnosed by blinded expert adjudication. The incidence of TEAMV-PD in all patients (1068 PRPC and 1223 CPC) was less for PRPC (1.7 %) than CPC (3.1%) with a treatment difference of –1.5% (95% confidence interval [CI], –2.7 to –0.2). In patients requiring ≥2 PCs, the incidence of TEAMV-PD was reduced for PRPC recipients compared with CPC recipients (treatment difference, –2.4%; 95% CI, –4.2 to –0.6). CSPAE increased with increasing PC exposure but were not significantly different between the cohorts. For patients receiving ≥2 platelet transfusions, TEARDS occurred in 1.3% PRPC and 2.6% CPC recipients (P = .086). Bayesian analysis demonstrated PRPC may be superior in reducing TEAMV-PD and TEARDS for platelet transfusion recipients compared with CPC recipients, with 99.2% and 88.8% probability, respectively. In this study, PRPC compared with CPC demonstrated high probability of reduced severe pulmonary injury requiring assisted mechanical ventilation in patients with hematology disorders dependent on platelet transfusion. This trial was registered at www.ClinicalTrials.gov as #NCT02549222.
Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Alexander, Barbara D. , Arendrup, Maiken Cavling , Babady, Esther , Balada-Llasat, Joan-Miquel, Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Fuller, Jeff, Gibas, Connie Fe C., Glasgow, Heather, Groll, Andreas H. , Haase, Gerhard , Hanson, Kimberly E. , Harrington, Amanda, Hayden, Randall T. , Hubka, Vít , Johnson, Kristie, Li, Ruoyu , Lanternier, Fanny , Lee, Francesca , Luethy, Paul M. , Kwon‐Chung, Kyung J., Palavecino, Elizabeth , Pancholi, Preeti , Pappas, Peter G. , Procop, Gary W. , Rhoads, Daniel D. , Riedel, Stefan , Stevens, Bryan S. , Sullivan, Kaede Ota, Vergidis, Paschalis , Roilides, Emmanuel , Seyedmousavi, Amir, Tao, Lili , Vicente, Vânia Aparecida , Vitale, Roxana G. , Wengenack, Nancy L. , Westblade, Lars F. , White, Lewis, Wojewoda, Christina , Babady, N. Esther , Seyedmousavi, Seyedmojtaba , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Groll, Andreas H , Hanson, Kimberly , Hayden, Randall T , Hoenigl, Martin , Kus, Julianne V , Meis, Jacques F , Leal, Sixto M , Lockhart, Shawn R. , Kwon-Chung, Kyung J , Nguyen, M Hong , Palavecino, Elizabeth , Pancholi, Preeti , Rhoads, Daniel D , Riedel, Stefan , Vergidis, Paschalis , Roilides, Emmanuel , Wengenack, Nancy L , Wiederhold, Nathan , White, Lewis , Wojewoda, Christina M , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Luethy, Paul , Bai, Feng‐Yan , Chowdhary, Anuradha , Clark, Andrew, Dingle, Tanis C. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Gräser, Yvonne , Guillot, Jacques , Hawksworth, David L. , Hoenigl, Martin , Kus, Julianne V. , Lackner, Michaela , Leal, Sixto M. , Martin, Isabella W. , Meyer, Wieland , Ostrosky‐Zeichner, Luis , Redhead, Scott A. , Stevens, Bryan, Wang, Qiming , Wiederhold, Nathan P. , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | March 5, 2024 | Volume: 62 | Issue: 4 | Pages: No page available

10.1128/jcm.01625-23 | PMID 38441056 Get It

Abstract 082: Angiographic Features and Treatment Results of Dural Arteriovenous Fistulas Cognitive Impairment
Sanchez, Sebastian , Ching‐Jen, Chen, Sheehan, Jason P. , Kim, Louis J. , Abecassis, I, Meyer, Michael, Guniganti, Ridhima , Pabaney, A, Brinjikji, Waleed , Durnford, Andrew , Zipfel, Gregory J. , Gross, Bradley A. , Wendt, Linder , Hayakawa, M. , Samaniego, Edgar A , Kim, Louis J. , Levitt, Michael R. , Lanzino, Giuseppe , Giordan, Enrico , Bulters, Diederik , Ortega-Gutierrez, Santiago , Fox, W Christopher , Derdeyn, Colin P. , Smith, Jessica , Gross, Bradley , Amin-Hanjani, Sepideh , Alaraj, Ali

Mayo Clinic

Stroke: Vascular and Interventional Neurology | March 5, 2024 | Volume: 3 | Issue: S2 | Pages: No page available

10.1161/svin.03.suppl_2.082 Get It

Introduction Dural arteriovenous fistulas (dAVFs) have been associated with rapidly progressive dementia in relatively young patients. However, the specific angioarchitecture and characteristics of these dAVFs remain to be fully described. To better understand the specific characteristics of dAVFs associated with cognitive impairment (dAVF‐CI), we utilized the CONDOR multicenter database, which provides a large cohort of dAVF available. By analyzing data from patients with dAVFs‐ CI, we aimed to identify the key features distinguishing these cases and elaborate on the pathophysiology of dAVF‐CI. Methods CONDOR is an international multicenter database comprising 1077 (dAVFs) from 14 international centers. We conducted a retrospective analysis of the CONDOR database, focusing on patients diagnosed with dAVFs‐CI. Propensity score matching analysis was performed to compare Borden type II and type III dAVFs with and without cognitive impairment as control groups. Only dAVFs with cortical venous drainage were included as this aggressive subtype can present with non‐hemorrhagic neurologic deficits. Additionally, logistic regression was then employed to identify significant characteristics associated with dAVF‐CI. Results A total of 60 patients with dAVF‐CI and 60 control dAVFs were included in the analysis. The patients with dAVF‐CI had a mean age of 58 ± 18 years. It was found that all cases of dAVF‐CI exhibited venous hypertension. Additionally, there was a significant association between sinus stenosis and dAVF‐CI (OR: 2.85, 95% CI: 1.16‐7.55, p = 0.027). Moreover, dAVF‐CI cases were characterized by the presence of multiple arteriovenous shunts, with more arterial feeders (OR 1.56, 95% CI 1.22‐2.05, p <0.001) and draining veins (OR 2.05, 95% CI 1.05‐4.46, p = 0.004) compared to the control dAVFs. Venous ectasia was also found to be associated with dAVF‐CI (OR 2.38, 95% CI 1.13‐5.11, p= 0.024). Finally, some patients in which successful dAVF closure was achieved had symptom resolution during follow‐up (OR 2.86, 95% CI 0.85‐9.56, p = 0.09). Conclusion dAVFs‐CI tend to occur in relatively young patients and are characterized by the presence of venous hypertension. The development of sinus stenosis and venous ectasia further hinders proper drainage, contributing to the persistence of venous hypertension. Venous hypertension may impair critical structures such as the thalamus or the cortex leading to rapid cognitive impairment. Successful treatment of dAVFs‐CI can potentially reverse symptoms. Nonetheless, some dAVF‐CI may have persistent symptoms due to chronic hypertension and infarction.
Abstract A004: GTP signaling links metabolism, DNA repair, and responses to genotoxic stress
Zhou, Weihua , Zhao, Zitong , Lin, Angelica , Xu, Jie , Wilder-Romans, Kari , Yang, Annabel , Solanki, Sumeet , Yao, Yangyang , Peterson, Erik , Korimerla, Navyateja , Werner, Christian K. , Liang, Jessica , Jacobson, Janna , O'Brien, Alexandra, Elaimy, Ameer L. , Ferris, Sean P. , Zhao, Shuang G. , Zhang, Shuqun , Morgan, Meredith A. , Lawrence, Theodore S. , Lyssiotis, Costas A. , Peters‐Golden, Marc , Wahl, Daniel , Lawrence, Theodore S , Lyssiotis, Costas A , Yang, John, Scott, Andrew J. , Li, Jing , Speth, Jennifer M. , Walker, Natalie , Kothari, Ayesha U. , Palavalasa, Sravya , Zhao, Shuang G , Sarkaria, Jann N. , Győrffy, Balázs , Al‐Holou, Wajd N. , Umemura, Yoshie , Shah, Yatrik M

Mayo Clinic

Cancer Research | March 4, 2024 | Volume: 84 | Issue: 5_Supplement_1 | Pages: A004-A004

10.1158/1538-7445.brain23-a004 Get It

Abstract OBJECTIVE: We sought to define the mechanisms by which purines regulate DNA repair and therapy response. METHODS: Phosphoproteomics was used to identify GTP-dependent (de)phosphorylation events after radiation (RT) and antibodies generated against novel sites. Animal models of glioblastoma (GBM) and normal tissues were used to assess DNA repair and treatment responses in vivo. RESULTS: Pharmacogenomic inhibition of GTP (but not ATP) synthesis sensitized GBM cells to RT by inhibiting the activity of non-homologous end joining, but not homologous recombination. We found a GTP-dependent RT-induced dephosphorylation event on Abl interactor 1 (Abi-1) serine 323 (S323) using phosphoproteomics. We generated a new antibody for p-Abi-1 (S323), validated its specificity, and confirmed that RT causes a GTP-dependent dephosphorylation of Abi-1 (S323). Knockout of Abi-1 slowed RT-induced double-strand break (DSB) repair, and this was rescued by re-expression of dephosphomimetic Abi-1 (S323A) but not phosphomimetic Abi-1 (S323D). Abi-1 canonically binds to G protein Rac1. Expression of constitutively active Rac1 promoted but dominant negative Rac1 blocked the dephosphorylation of Abi-1 (S323) and DSB repair. Knock-down or inhibition of protein phosphatase 5 reversed the GTP- and Rac1-mediated dephosphorylation of Abi-1 and DSB repair. In GBM PDX samples, p-Abi-1 (S323) levels negatively correlated with Rac1 activity and predicted favorable efficacy of genotoxic treatments. In orthotopic GBM mouse models, inhibiting Rac1 enhanced RT responses and suppressed Abi-1 (S323) dephosphorylation. Abi-1 knockout enhanced efficacy of genotoxic treatments and could be rescued by Abi-1 S323A (but not Abi-1 S323D) re-expression. This regulation is generalizable beyond brain cancer, as GTP supplementation promoted DNA repair and p-Abi1 (S323) dephosphorylation in non-malignant cells and protected mice from RT-mediated gastrointestinal injury and bleomycin-induced pulmonary fibrosis. CONCLUSION: The GTP-Rac1-PP5-Abi-1 signaling axis links metabolism and DNA repair. Disrupting this pathway can overcome cancer resistance to genotoxic therapy while augmenting it can mitigate genotoxic injury of normal tissues. Citation Format: Weihua Zhou, Zitong Zhao, Angelica Lin, John Yang, Jie Xu, Kari Wilder-Romans, Annabel Yang, Andrew J. Scott, Jing Li, Sumeet Solanki, Jennifer Speth, Natalie Walker, Ayesha U. Kothari, Yangyang Yao, Erik R. Peterson, Navyateja Korimerla, Christian K. Werner, Jessica Liang, Janna Jacobson, Sravya Palavalasa, Alexandra M Obrien, Ameer L Elaimy, Sean P. Ferris, Shuang G. Zhao, Jann N. Sarkaria, Balázs Győrffy, Shuqun Zhang, Wajd N. Al-Holou, Yoshie Umemura, Meredith A Morgan, Theodore S. Lawrence, Costas A. Lyssiotis, Marc Peters-Golden, Yatrik M. Shah, Daniel R. Wahl. GTP signaling links metabolism, DNA repair, and responses to genotoxic stress [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr A004.
A practical guide to the development and deployment of deep learning models for the orthopaedic surgeon: Part III, focus on registry creation, diagnosis, and data privacy
Oeding, Jacob F. , Yang, Linjun , Samuelsson, Kristian , Pearle, Andrew D. , Kelly, Bryan T. , Pareek, Ayoosh , Yang, Linjun , Sanchez-Sotelo, Joaquin, Samuelsson, Kristian , Oeding, Jacob F , Yang, Linjun , Sánchez‐Sotelo, Joaquín , Camp, Christopher L. , Karlsson, Jón , Ranawat, Anil S.

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | March 1, 2024 | Volume: 32 | Issue: 3 | Pages: 518-528

10.1002/ksa.12085 | PMID 38426614 Get It

AbstractDeep learning is a subset of artificial intelligence (AI) with enormous potential to transform orthopaedic surgery. As has already become evident with the deployment of Large Language Models (LLMs) like ChatGPT (OpenAI Inc.), deep learning can rapidly enter clinical and surgical practices. As such, it is imperative that orthopaedic surgeons acquire a deeper understanding of the technical terminology, capabilities and limitations associated with deep learning models. The focus of this series thus far has been providing surgeons with an overview of the steps needed to implement a deep learning‐based pipeline, emphasizing some of the important technical details for surgeons to understand as they encounter, evaluate or lead deep learning projects. However, this series would be remiss without providing practical examples of how deep learning models have begun to be deployed and highlighting the areas where the authors feel deep learning may have the most profound potential. While computer vision applications of deep learning were the focus of Parts I and II, due to the enormous impact that natural language processing (NLP) has had in recent months, NLP‐based deep learning models are also discussed in this final part of the series. In this review, three applications that the authors believe can be impacted the most by deep learning but with which many surgeons may not be familiar are discussed: (1) registry construction, (2) diagnostic AI and (3) data privacy. Deep learning‐based registry construction will be essential for the development of more impactful clinical applications, with diagnostic AI being one of those applications likely to augment clinical decision‐making in the near future. As the applications of deep learning continue to grow, the protection of patient information will become increasingly essential; as such, applications of deep learning to enhance data privacy are likely to become more important than ever before.Level of Evidence: Level IV.
Dural arteriovenous fistulas are not observed to convert to a higher grade after partial embolization
Walker, Erin , Srienc, Anja I. , Lew, Daphne , Guniganti, Ridhima , Brinjikji, Waleed , Hayakawa, M. , Samaniego, Edgar A. , Lai, Rosalind, Sheehan, Jason P. , Starke, Robert M., Abla, Adib A. , Gross, Bradley A. , Albuquerque, Felipe C , Lawton, Michael T. , Kim, Louis J. , Levitt, Michael R. , Alaraj, Ali , Winkler, Ethan A. , Polifka, Adam , Bulters, Diederik , Durnford, Andrew , Satomi, Junichiro, Tada, Yoshiteru , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Zipfel, Gregory J. , Levitt, Michael R , Alaraj, Ali , Samaniego, Edgar A , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Lanzino, Giuseppe , Derdeyn, Colin P. , Du, Rose , Abdelsalam, Ahmed , Gross, Bradley , Kim, Louis J. , Amin-Hanjani, Sepideh , Fox, W Christopher , Hall, Samuel , Chen, Ching‐Jen , Becerril‐Gaitan, Andrea , Osbun, Joshua W

Mayo Clinic

Neurosurgical Focus | March 1, 2024 | Volume: 56 | Issue: 3 | Pages: E8

10.3171/2024.1.focus23745 | PMID 38428013 Get It

OBJECTIVE Borden-Shucart type I dural arteriovenous fistulas (dAVFs) lack cortical venous drainage and occasionally necessitate intervention depending on patient symptoms. Conversion is the rare transformation of a low-grade dAVF to a higher grade. Factors associated with increased risk of dAVF conversion to a higher grade are poorly understood. The authors hypothesized that partial treatment of type I dAVFs is an independent risk factor for conversion. METHODS The multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research database was used to perform a retrospective analysis of all patients with type I dAVFs. RESULTS Three hundred fifty-eight (33.2%) of 1077 patients had type I dAVFs. Of those 358 patients, 206 received endovascular treatment and 131 were not treated. Two (2.2%) of 91 patients receiving partial endovascular treatment for a low-grade dAVF experienced conversion to a higher grade, 2 (1.5%) of 131 who were not treated experienced conversion, and none (0%) of 115 patients who received complete endovascular treatment experienced dAVF conversion. The majority of converted dAVFs localized to the transverse-sigmoid sinus and all received embolization as part of their treatment. CONCLUSIONS Partial treatment of type I dAVFs does not appear to be significantly associated with conversion to a higher grade.